The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
- Gilead Revises Veklury Label Warning of Coadministration with Hydroxychloroquine or Chloroquine
September 2, 2020
- Taisho, Takeda to Wind Up Japan Distribution Deal for Biofermin’s Prescription Drugs
September 2, 2020
- Fujifilm Files Radiopharmaceutical Drug F-1515 in Japan
September 1, 2020
- Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
September 1, 2020
- Sanofi’s Sarclisa Hits Japan Market, Zeria Launches Ferinject
September 1, 2020
- Edoxaban Hits PIII Goal in Very Elderly Patients: Daiichi Sankyo
September 1, 2020
- Sales Rep Promotions Up in July, but Online Channels Down: Intage
August 31, 2020
- Shionogi Pharma Files Baktar Small-Sized Tablets to Improve Compliance in Children
August 31, 2020
- Nichi-Iko to Revamp Quality Control System after Massive Recalls by Leveraging Teva Takeda Plant
August 28, 2020
- MEDRx/D. Western Therapeutics’ Lidocaine Tape Formulation Filed for Post-Herpetic Neuralgia in US
August 28, 2020
- 2 More HIF-PH Inhibitors, Enerzair, Enspryng and More Now Available in Japan
August 27, 2020
- JCR to Commence Full-Fledged Biz for Lysosomal Storage Disorder Meds in Brazil
August 27, 2020
- Kowa’s Glaucoma Med Glanatec Approved in Thailand
August 27, 2020
- As Entresto Hits Japan Market, Novartis Poised to Tap All Channels to Push Global Blockbuster
August 26, 2020
- Carna Bio Starts First-in-Human Trial for BTK Inhibitor
August 26, 2020
- Sanwa Kagaku Files SHPT Med for Japan Approval
August 26, 2020
- Drug Makers Taking Mixed Disclosure Policies for Coronavirus Infections
August 25, 2020
- Takeda to Sell Japan OTC Biz to Blackstone, Weber Says It’s the Right Choice
August 25, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…